OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Orexin receptors as therapeutic drug targets
Anthony L. Gotter, Anthony J. Roecker, Richard Hargreaves, et al.
Progress in brain research (2012), pp. 163-188
Closed Access | Times Cited: 95
Anthony L. Gotter, Anthony J. Roecker, Richard Hargreaves, et al.
Progress in brain research (2012), pp. 163-188
Closed Access | Times Cited: 95
Showing 1-25 of 95 citing articles:
Pathophysiology of Migraine: A Disorder of Sensory Processing
Peter J. Goadsby, Philip R. Holland, Margarida Martins-Oliveira, et al.
Physiological Reviews (2017) Vol. 97, Iss. 2, pp. 553-622
Open Access | Times Cited: 1519
Peter J. Goadsby, Philip R. Holland, Margarida Martins-Oliveira, et al.
Physiological Reviews (2017) Vol. 97, Iss. 2, pp. 553-622
Open Access | Times Cited: 1519
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
S P H Alexander, Helen E. Benson, Elena Faccenda, et al.
British Journal of Pharmacology (2013) Vol. 170, Iss. 8, pp. 1459-1581
Open Access | Times Cited: 552
S P H Alexander, Helen E. Benson, Elena Faccenda, et al.
British Journal of Pharmacology (2013) Vol. 170, Iss. 8, pp. 1459-1581
Open Access | Times Cited: 552
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial
David Michelson, Ellen Snyder, Erin M. Paradis, et al.
The Lancet Neurology (2014) Vol. 13, Iss. 5, pp. 461-471
Closed Access | Times Cited: 480
David Michelson, Ellen Snyder, Erin M. Paradis, et al.
The Lancet Neurology (2014) Vol. 13, Iss. 5, pp. 461-471
Closed Access | Times Cited: 480
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials
W. Joseph Herring, Kathryn M. Connor, Neely Ivgy-May, et al.
Biological Psychiatry (2014) Vol. 79, Iss. 2, pp. 136-148
Closed Access | Times Cited: 257
W. Joseph Herring, Kathryn M. Connor, Neely Ivgy-May, et al.
Biological Psychiatry (2014) Vol. 79, Iss. 2, pp. 136-148
Closed Access | Times Cited: 257
Multiple roles for orexin/hypocretin in addiction
Stephen V. Mahler, Rachel J. Smith, David E. Moorman, et al.
Progress in brain research (2012), pp. 79-121
Open Access | Times Cited: 211
Stephen V. Mahler, Rachel J. Smith, David E. Moorman, et al.
Progress in brain research (2012), pp. 79-121
Open Access | Times Cited: 211
How to fix a broken clock
Analyne M. Schroeder, Christopher S. Colwell
Trends in Pharmacological Sciences (2013) Vol. 34, Iss. 11, pp. 605-619
Open Access | Times Cited: 183
Analyne M. Schroeder, Christopher S. Colwell
Trends in Pharmacological Sciences (2013) Vol. 34, Iss. 11, pp. 605-619
Open Access | Times Cited: 183
Modeling Human Disease with Pluripotent Stem Cells: from Genome Association to Function
Florian T. Merkle, Kevin Eggan
Cell stem cell (2013) Vol. 12, Iss. 6, pp. 656-668
Open Access | Times Cited: 182
Florian T. Merkle, Kevin Eggan
Cell stem cell (2013) Vol. 12, Iss. 6, pp. 656-668
Open Access | Times Cited: 182
Discovery and development of orexin receptor antagonists as therapeutics for insomnia
Christopher J. Winrow, John J. Renger
British Journal of Pharmacology (2013) Vol. 171, Iss. 2, pp. 283-293
Open Access | Times Cited: 144
Christopher J. Winrow, John J. Renger
British Journal of Pharmacology (2013) Vol. 171, Iss. 2, pp. 283-293
Open Access | Times Cited: 144
Generation of neuropeptidergic hypothalamic neurons from human pluripotent stem cells
Florian T. Merkle, Asif Maroof, Takafumi Wataya, et al.
Development (2015) Vol. 142, Iss. 4, pp. 633-643
Open Access | Times Cited: 141
Florian T. Merkle, Asif Maroof, Takafumi Wataya, et al.
Development (2015) Vol. 142, Iss. 4, pp. 633-643
Open Access | Times Cited: 141
Migraine and neuropeptides
János Tajti, Délia Szok, Zsófia Majláth, et al.
Neuropeptides (2015) Vol. 52, pp. 19-30
Open Access | Times Cited: 122
János Tajti, Délia Szok, Zsófia Majláth, et al.
Neuropeptides (2015) Vol. 52, pp. 19-30
Open Access | Times Cited: 122
Orexins and stress
Laura A. Grafe, Seema Bhatnagar
Frontiers in Neuroendocrinology (2018) Vol. 51, pp. 132-145
Open Access | Times Cited: 106
Laura A. Grafe, Seema Bhatnagar
Frontiers in Neuroendocrinology (2018) Vol. 51, pp. 132-145
Open Access | Times Cited: 106
Recent Perspectives on Sex Differences in Compulsion-Like and Binge Alcohol Drinking
Anna K. Radke, Elizabeth A. Sneddon, Raizel M. Frasier, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3788-3788
Open Access | Times Cited: 86
Anna K. Radke, Elizabeth A. Sneddon, Raizel M. Frasier, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3788-3788
Open Access | Times Cited: 86
Understanding the Biological Relationship between Migraine and Depression
Adrián Viudez‐Martínez, Abraham B. Torregrosa, Francisco Navarrete, et al.
Biomolecules (2024) Vol. 14, Iss. 2, pp. 163-163
Open Access | Times Cited: 9
Adrián Viudez‐Martínez, Abraham B. Torregrosa, Francisco Navarrete, et al.
Biomolecules (2024) Vol. 14, Iss. 2, pp. 163-163
Open Access | Times Cited: 9
Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia
Claudia Betschart, Samuel Hintermann, Dirk Behnke, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 19, pp. 7590-7607
Closed Access | Times Cited: 98
Claudia Betschart, Samuel Hintermann, Dirk Behnke, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 19, pp. 7590-7607
Closed Access | Times Cited: 98
The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold
Anthony L. Gotter, Christopher J. Winrow, Joseph Brunner, et al.
BMC Neuroscience (2013) Vol. 14, Iss. 1
Open Access | Times Cited: 88
Anthony L. Gotter, Christopher J. Winrow, Joseph Brunner, et al.
BMC Neuroscience (2013) Vol. 14, Iss. 1
Open Access | Times Cited: 88
Evidence for orexinergic mechanisms in migraine
Jan Hoffmann, Weera Supronsinchai, Simon Akerman, et al.
Neurobiology of Disease (2014) Vol. 74, pp. 137-143
Closed Access | Times Cited: 83
Jan Hoffmann, Weera Supronsinchai, Simon Akerman, et al.
Neurobiology of Disease (2014) Vol. 74, pp. 137-143
Closed Access | Times Cited: 83
Selective orexin receptor antagonists
Terry P. Lebold, Pascal Bonaventure, Brock T. Shireman
Bioorganic & Medicinal Chemistry Letters (2013) Vol. 23, Iss. 17, pp. 4761-4769
Closed Access | Times Cited: 73
Terry P. Lebold, Pascal Bonaventure, Brock T. Shireman
Bioorganic & Medicinal Chemistry Letters (2013) Vol. 23, Iss. 17, pp. 4761-4769
Closed Access | Times Cited: 73
Exercise Influence on Hippocampal Function: Possible Involvement of Orexin-A
Sergio Chieffi, Giovanni Messina, Ines Villano, et al.
Frontiers in Physiology (2017) Vol. 8
Open Access | Times Cited: 72
Sergio Chieffi, Giovanni Messina, Ines Villano, et al.
Frontiers in Physiology (2017) Vol. 8
Open Access | Times Cited: 72
Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data
Ellen Snyder, Junshui Ma, Vladimir Svetnik, et al.
Sleep Medicine (2015) Vol. 19, pp. 93-100
Closed Access | Times Cited: 64
Ellen Snyder, Junshui Ma, Vladimir Svetnik, et al.
Sleep Medicine (2015) Vol. 19, pp. 93-100
Closed Access | Times Cited: 64
Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia
Anthony J. Roecker, Swati P. Mercer, John D. Schreier, et al.
ChemMedChem (2013) Vol. 9, Iss. 2, pp. 311-322
Closed Access | Times Cited: 62
Anthony J. Roecker, Swati P. Mercer, John D. Schreier, et al.
ChemMedChem (2013) Vol. 9, Iss. 2, pp. 311-322
Closed Access | Times Cited: 62
OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2-INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES
Philip L. Johnson, Lauren M. Federici, Stephanie D. Fitz, et al.
Depression and Anxiety (2015) Vol. 32, Iss. 9, pp. 671-683
Open Access | Times Cited: 62
Philip L. Johnson, Lauren M. Federici, Stephanie D. Fitz, et al.
Depression and Anxiety (2015) Vol. 32, Iss. 9, pp. 671-683
Open Access | Times Cited: 62
Current and novel insights into the neurophysiology of migraine and its implications for therapeutics
Simon Akerman, Marcela Romero‐Reyes, Philip R. Holland
Pharmacology & Therapeutics (2016) Vol. 172, pp. 151-170
Closed Access | Times Cited: 58
Simon Akerman, Marcela Romero‐Reyes, Philip R. Holland
Pharmacology & Therapeutics (2016) Vol. 172, pp. 151-170
Closed Access | Times Cited: 58
Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs
Jonathan Ong, Diana Y. Wei, Peter J. Goadsby
Drugs (2018) Vol. 78, Iss. 4, pp. 411-437
Closed Access | Times Cited: 58
Jonathan Ong, Diana Y. Wei, Peter J. Goadsby
Drugs (2018) Vol. 78, Iss. 4, pp. 411-437
Closed Access | Times Cited: 58
Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use
Emilio Merlo Pich, Sergio Melotto
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 57
Emilio Merlo Pich, Sergio Melotto
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 57
Suvorexant for the treatment of insomnia
Laura H. Jacobson, Gabrielle E. Callander, Daniël Hoyer
Expert Review of Clinical Pharmacology (2014) Vol. 7, Iss. 6, pp. 711-730
Closed Access | Times Cited: 52
Laura H. Jacobson, Gabrielle E. Callander, Daniël Hoyer
Expert Review of Clinical Pharmacology (2014) Vol. 7, Iss. 6, pp. 711-730
Closed Access | Times Cited: 52
